SK Biopharmaceuticals
Tracked across 6 events · 37 articles · First seen Jul 13, 2026 · Last active Sep 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Sino Biopharmaceutical is the central entity, announcing its new global brand and highlighting its globalization strategy. The company's licensing deals and brand launch are expected to strengthen its market position and investor sentiment.
Jul 20, 2026 · 6 articles
Business
Impact: Caliway is the developer of CBL-514 and the primary beneficiary. FDA clearance and Phase 3 enrollment advance its pipeline, potentially leading to the first non-surgical fat reduction drug, which could significantly increase its market value.
Jul 20, 2026 · 7 articles
Business
Impact: SK Biopharmaceuticals recently partnered with Cipla on a different oncology asset, highlighting Cipla's strategy of in-licensing from Chinese firms.
Sep 03, 2026 · 6 articles
Business
Impact: Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Jul 20, 2026 · 6 articles
Business
Impact: SK Biopharmaceuticals is mentioned as a prior collaborator with Insilico, but is not directly involved in this event.
Jul 13, 2026 · 6 articles
Tech
Insilico Medicine announced on September 9-10, 2026 that it has dosed the first patient with Rentosertib (ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF), at United Medical College…
Impact: SK Biopharmaceuticals is listed among Insilico's collaboration partners. The event has minimal direct impact on SK Biopharmaceuticals.
Sep 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track SK Biopharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard